{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:20:44Z","timestamp":1790799644075,"version":"4.1.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.587773","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T06:52:41Z","timestamp":1605768761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification"],"prefix":"10.3389","volume":"7","author":[{"given":"Changyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingxian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingguo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e000782","DOI":"10.1136\/rmdopen-2018-000788","article-title":"Systemic sclerosis: state of the art on clinical practice guidelines","volume":"4","author":"Smith","year":"2018","journal-title":"RMD Open."},{"key":"B3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1073\/pnas.77.3.1627","article-title":"Autoantibody to centromere (kinetochore) in scleroderma sera","volume":"77","author":"Moroi","year":"1980","journal-title":"Proc Natl Acad Sci USA."},{"key":"B5","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.1002\/chem.200903108","article-title":"Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma","volume":"254","author":"Douvas","year":"1979","journal-title":"J Biol Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity."},{"key":"B7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/1346-8138.14162","article-title":"Diagnostic criteria, severity classification and guidelines of systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.autrev.2014.11.002","article-title":"Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early\/early SSc or pre-SSc)","volume":"14","author":"Valentini","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-017-0684-2","article-title":"Very early systemic sclerosis and pre-systemic sclerosis: definition, recognition, clinical relevance and future directions","volume":"19","author":"Bellando-Randone","year":"2017","journal-title":"Curr Rheumatol Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/annrheumdis-2015-eular.1915","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective eustar cohort of patients with systemic sclerosis","volume":"74","author":"Sobanski","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/BOR.0000000000000747","article-title":"Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors","volume":"32","author":"Sobanski","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF01451042","article-title":"How useful are serum autoantibodies in the diagnosis and prognosis of systemic sclerosis?","volume":"17","author":"Meyer","year":"1998","journal-title":"Clin Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.160106","article-title":"Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis","volume":"43","author":"Nandiwada","year":"2016","journal-title":"J Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.clinre.2013.04.005","article-title":"Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis","volume":"37","author":"Liberal","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1756-185X.13439","article-title":"Initial presentation determines clinical entity in patients with anti-centromere antibody positivity","volume":"22","author":"Tsukamoto","year":"2019","journal-title":"Int J Rheum Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/rheumatology\/kez486","article-title":"Racial differences in systemic sclerosis disease presentation: a European scleroderma trials and research group study","volume":"59","author":"Jaeger","year":"2020","journal-title":"Rheumatology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/1756-185X.13060","article-title":"Relevance of clinical and autoantibody profiles in systemic sclerosis among thais","volume":"20","author":"Foocharoen","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2020.1751408","article-title":"Clinical course of Japanese patients with early systemic sclerosis: a multicenter, prospective, observational study","volume":"21","author":"Utsunomiya","year":"2020","journal-title":"Modern Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10067-012-2145-7","article-title":"Clinical and serological features of systemic sclerosis in a Chinese cohort","volume":"32","author":"Wang","year":"2013","journal-title":"Clin Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/1756-185X.12492","article-title":"Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I","volume":"19","author":"Foocharoen","year":"2016","journal-title":"Int J Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1097\/01.rhu.0000173620.95740.e2","article-title":"Clinical and serological heterogeneity in patients with anticentromere antibodies","volume":"32","author":"Miyawaki","year":"2005","journal-title":"J Rheumatol."},{"key":"B24","unstructured":"Systemic sclerosis progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of the scleroderma spectrum4047 FerriC GiuggioliD GuiducciS LumettiF BajocchiG MagnaniL Clin Exp Rheumatol.1252020"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.38994","article-title":"Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies","volume":"67","author":"Hamaguchi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/ijd.13032","article-title":"RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis","volume":"55","author":"Terras","year":"2016","journal-title":"Int J Dermatol."},{"key":"B28","unstructured":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain4148 Callejas-MoragaEL Guill\u00e9n-Del-CastilloA Mar\u00edn-S\u00e1nchezAM Roca-HerreraM BaladaE Tolosa-VilellaC 30767873Clin Exp Rheumatol.1192019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.17219\/acem\/64334","article-title":"Systemic sclerosis sine scleroderma","volume":"26","author":"Kucharz","year":"2017","journal-title":"Adv Clin Exp Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3899\/jrheum.121089","article-title":"Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis","volume":"40","author":"Sulli","year":"2013","journal-title":"J Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10067-014-2616-0","article-title":"Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease","volume":"33","author":"Gunn","year":"2014","journal-title":"Clin Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","article-title":"Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma","volume":"18","author":"Fava","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5455\/medarh.2015.69.153-156","article-title":"Oral manifestations of systemic sclerosis and correlation with anti-topoisomerase I antibodies (SCL-70)","volume":"69","author":"Bajraktari","year":"2015","journal-title":"Med Arch."},{"key":"B35","unstructured":"The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis40712 Radi\u0107M Martinovi\u0107 KaliternaD Ljuti\u0107D 16956431Clin Exp Rheumatol.242006"},{"key":"B36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/RHU.0000000000000167","article-title":"Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease","volume":"20","author":"Bhavsar","year":"2014","journal-title":"J Clin Rheumatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3899\/jrheum.160867","article-title":"Cardiopulmonary disease development in Anti-RNA polymerase III-positive systemic sclerosis: comparative analyses from an unselected, prospective patient cohort","volume":"44","author":"Hoffmann-Vold","year":"2017","journal-title":"J Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00296-017-3654-0","article-title":"Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment","volume":"37","author":"Dall'Ara","year":"2017","journal-title":"Rheumatol Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1346-8138.13292","article-title":"Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis","volume":"43","author":"Saigusa","year":"2016","journal-title":"J Dermatol."},{"key":"B40","unstructured":"Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease7174 ShahAA RosenA HummersLK MayBJ KaushivaA RodenRBS Clin Exp Rheumatol.1062017"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1588084","DOI":"10.1080\/2162402X.2019.1588084","article-title":"Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival","volume":"8","author":"Watad","year":"2019","journal-title":"Oncoimmunology."},{"key":"B42","unstructured":"Overlap of ACA-positive systemic sclerosis and Sj\u00f6gren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma27280 BaldiniC MoscaM Della RossaA PepeP NotarstefanoC FerroF 23343785Clin Exp Rheumatol.312013"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","article-title":"Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies","volume":"38","author":"Airo","year":"2011","journal-title":"J Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/1346-8138.12722","article-title":"Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies","volume":"42","author":"Motegi","year":"2015","journal-title":"J Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/1346-8138.12827","article-title":"Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis","volume":"42","author":"Saigusa","year":"2015","journal-title":"J Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.3389\/fimmu.2018.03112","article-title":"Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors","volume":"9","author":"Maria","year":"2018","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/08830189509056707","article-title":"HLA and autoimmunity in scleroderma (systemic sclerosis)","volume":"12","author":"Arnett","year":"1995","journal-title":"Int Rev Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0889-857X(05)70299-4","article-title":"Scleroderma epidemiology","volume":"22","author":"Mayes","year":"1996","journal-title":"Rheum Dis Clin North Am."},{"key":"B52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.17116\/terarkh201789520-25","article-title":"[The influence of STAT4 rs7574865 (G\/T) polymorphism on the risk of clinical and immunological phenotypes of systemic sclerosis in a Russian patient population: results of a pilot study]","volume":"89","author":"Krylov","year":"2017","journal-title":"Terapevticheskii Arkhiv."},{"key":"B53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/039463201302600220","article-title":"STAT4 is a genetic risk factor for systemic sclerosis in a Chinese population","volume":"26","author":"Yi","year":"2013","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1002\/art.24688","article-title":"STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis","volume":"60","author":"Dieud\u00e9","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1136\/ard.2005.048181","article-title":"Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population","volume":"65","author":"Wipff","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B56","unstructured":"Lack of association of the PTPN22 gene polymorphism R620W with systemic sclerosis3214 BaladaE Sime\u00f3n-AznarCP Serrano-AcedoS Mart\u00ednez-LostaoL Selva-O'CallaghanA Fonollosa-PlaV 16870103Clin Exp Rheumatol.242006"},{"key":"B57","unstructured":"The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population5204 RamirezM QuintanaG Diaz-GalloLM CaminosJ GarcesM CepedaL 22704547Clin Exp Rheumatol.302012"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1002\/art.22196","article-title":"Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis","volume":"54","author":"Gourh","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/art.23601","article-title":"The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis","volume":"58","author":"Dieud\u00e9","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/ard.2010.130138","article-title":"Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis","volume":"70","author":"Diaz-Gallo","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s11033-011-1074-x","article-title":"The association between the PTPN22 C1858T polymorphism and systemic sclerosis: a meta-analysis","volume":"39","author":"Lee","year":"2012","journal-title":"Mol Biol Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/hmg\/ddp119","article-title":"The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype","volume":"18","author":"Rueda","year":"2009","journal-title":"Hum Mol Genet."},{"key":"B63","unstructured":"Association study of B-cell marker gene polymorphisms in European Caucasian patients with systemic sclerosis83942 DawidowiczK Dieud\u00e9P AvouacJ WipffJ HachullaE DiotE 21961844Clin Exp Rheumatol292011"},{"key":"B64","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/art.20065","article-title":"The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B65","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10238-019-00569-4","article-title":"TNFA\u2212308G>A and\u2212238G>A polymorphisms and risk to systemic sclerosis: impact on TNF-\u03b1 serum levels, TNFA mRNA expression, and autoantibodies","volume":"19","author":"Lomel\u00ed-Nieto","year":"2019","journal-title":"Clin Exp Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/rheumatology\/kem057","article-title":"An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis","volume":"46","author":"Alkassab","year":"2007","journal-title":"Rheumatology."},{"key":"B67","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/annrheumdis-2011-200275","article-title":"Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis","volume":"71","author":"Carmona","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.2008.096719","article-title":"The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype","volume":"68","author":"Rueda","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3899\/jrheum.090421","article-title":"Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis","volume":"36","author":"Agarwal","year":"2009","journal-title":"J Rheumatol."},{"key":"B70","first-page":"269","article-title":"Th17 pathway genes polymorphisms in Algerian patients with systemic sclerosis","volume":"43","author":"Mellal","year":"2018","journal-title":"Acta Reumatol Portuguesa."},{"key":"B71","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3899\/jrheum.111270","article-title":"Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis","volume":"39","author":"Coustet","year":"2012","journal-title":"J Rheumatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0209343","DOI":"10.1371\/journal.pone.0209343","article-title":"A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility","volume":"13","author":"Gonz\u00e1lez-Serna","year":"2018","journal-title":"PLoS ONE."},{"key":"B73","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41584-019-0257-z","article-title":"Towards a new classification of systemic sclerosis","volume":"15","author":"Hinchcliff","year":"2019","journal-title":"Nat Rev Rheumatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.humimm.2016.10.017","article-title":"Genomic and genetic studies of systemic sclerosis: a systematic review","volume":"78","author":"Chairta","year":"2017","journal-title":"Hum Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/ar3029","article-title":"Clinical and serological evaluation of a novel CENP-A peptide based ELISA","volume":"12","author":"Mahler","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1529-0131(199902)42:2<275::AID-ANR9>3.0.CO;2-P","article-title":"Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes","volume":"42","author":"Kuwana","year":"1999","journal-title":"Arthritis Rheum."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/rheumatology\/kep215","article-title":"A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis","volume":"48","author":"Nihtyanova","year":"2009","journal-title":"Rheumatology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry","volume":"117","author":"Gourh","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B79","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/ard.2009.111906","article-title":"Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls","volume":"69","author":"Arnett","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/039463201302600318","article-title":"Association of HLA-DQB1*0501 with scleroderma and its clinical features in Chinese population","volume":"26","author":"Zhou","year":"2013","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B81","unstructured":"HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I\/III antibody: associations with subunit reactivities23927 KuwanaM PandeyJP SilverRM KawakamiY KaburakiJ 14677183J Rheumatol.302003"},{"key":"B82","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2249.1994.tb06552.x","article-title":"Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study","volume":"96","author":"McHugh","year":"1994","journal-title":"Clin Exp Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/ijd.12839","article-title":"Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis","volume":"55","author":"Xu","year":"2016","journal-title":"Int J Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/art.30171","article-title":"Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B85","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/jcm8030347","article-title":"Association of PTPN22 1858C\/T polymorphism with autoimmune diseases: a systematic review and bayesian approach","volume":"8","author":"Tizaoui","year":"2019","journal-title":"J Clin Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ng.79","article-title":"Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus","volume":"40","author":"Kozyrev","year":"2008","journal-title":"Nat Genet."},{"key":"B87","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.24244","article-title":"Study of functional variants of the BANK1 gene in rheumatoid arthritis","volume":"60","author":"Orozco","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B88","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1002\/art.24885","article-title":"BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4","volume":"60","author":"Dieud\u00e9","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.30379","article-title":"C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large French cohort and meta-analysis","volume":"63","author":"Coustet","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B90","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/ard.2009.118174","article-title":"BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians","volume":"69","author":"Rueda","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.imlet.2018.01.002","article-title":"Pathogenic roles of B lymphocytes in systemic sclerosis","volume":"195","author":"Yoshizaki","year":"2018","journal-title":"Immunol Lett."},{"key":"B92","doi-asserted-by":"publisher","first-page":"9328","DOI":"10.1073\/pnas.92.20.9328","article-title":"Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation","volume":"92","author":"Barger","year":"1995","journal-title":"Proc Natl. Acad Sci U S A."},{"key":"B93","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.humimm.2004.03.001","article-title":"Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C\/T polymorphism","volume":"65","author":"Parks","year":"2004","journal-title":"Hum Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.imlet.2004.08.002","article-title":"238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with systemic sclerosis","volume":"96","author":"Tolusso","year":"2005","journal-title":"Immunol Lett"},{"key":"B95","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ard.2009.116434","article-title":"Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis","volume":"69","author":"Gourh","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","article-title":"Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients","volume":"45","author":"Tan","year":"2006","journal-title":"Rheumatology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1002\/art.22010","article-title":"Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor beta","volume":"54","author":"Del Galdo","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B98","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/01.bor.0000245724.94887.c4","article-title":"The role of allograft inflammatory factor 1 in systemic sclerosis","volume":"18","author":"Del Galdo","year":"2006","journal-title":"Curr Opin Rheumatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1399-0039.2007.00830.x","article-title":"Allograft inflammatory factor-1 and tumor necrosis factor single nucleotide polymorphisms in systemic sclerosis","volume":"69","author":"Otieno","year":"2007","journal-title":"Tissue Antigens."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2019-215208","article-title":"Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/1756-185X.13175","article-title":"IRF7 gene expression profile and methylation of its promoter region in patients with systemic sclerosis","volume":"20","author":"Rezaei","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.jid.2017.04.028","article-title":"RXRB is an MHC-encoded susceptibility gene associated with anti-topoisomerase I antibody-positive systemic sclerosis","volume":"137","author":"Oka","year":"2017","journal-title":"J Investigat Dermatol."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12455","article-title":"Retinoic acid for treatment of systemic sclerosis and morphea: a literature review","author":"Thomas","year":"2017","journal-title":"Dermatol Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-140-1-200401060-00010","article-title":"Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis","volume":"140","author":"Jimenez","year":"2004","journal-title":"Ann Intern Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B106","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00296-013-2844-7","article-title":"The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon","volume":"33","author":"Pavlov-Dolijanovic","year":"2013","journal-title":"Rheumatol Int."},{"key":"B107","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12016-012-8331-1","article-title":"Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma","volume":"43","author":"Moinzadeh","year":"2012","journal-title":"Clin Rev Allergy Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar4236","article-title":"Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers","volume":"15","author":"Valentini","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/acr.22304","article-title":"Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and\/or capillaroscopic positivity","volume":"66","author":"Valentini","year":"2014","journal-title":"Arthritis Care Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","article-title":"Thinking outside the box\u2013the associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect","volume":"45","author":"Srivastava","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"B111","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective european scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.clinthera.2016.02.029","article-title":"The alarmin properties of DNA and DNA-associated nuclear proteins","volume":"38","author":"Magna","year":"2016","journal-title":"Clin Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"B116","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/08916934.2016.1230848","article-title":"Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis","volume":"49","author":"Mehta","year":"2016","journal-title":"Autoimmunity."},{"key":"B117","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin Exp Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1002\/art.22972","article-title":"The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells","volume":"56","author":"Robitaille","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/art.24765","article-title":"Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells","volume":"60","author":"Robitaille","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B120","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.21646","article-title":"DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients","volume":"54","author":"H\u00e9nault","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B121","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.autrev.2009.02.018","article-title":"Anti-topoisomerase I autoantibodies in systemic sclerosis","volume":"8","author":"Cz\u00f6mp\u00f6ly","year":"2009","journal-title":"Autoimmun Rev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.33377","article-title":"The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts","volume":"64","author":"Arcand","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B123","doi-asserted-by":"publisher","first-page":"102515","DOI":"10.1016\/j.autrev.2020.102515","article-title":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","volume":"19","author":"Smeets","year":"2020","journal-title":"Autoimmun Rev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.587773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T20:07:06Z","timestamp":1669666026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.587773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":123,"alternative-id":["10.3389\/fmed.2020.587773"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.587773","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"article-number":"587773"}}